RxDoctor Payments Data

Elaine Steffensen

Optometrist · Houston, TXNPI 1356993067

Payments from drug & device makers

$5,005in general payments, 2019–2025

Across 109 payments — averaging $45.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Bausch & Lomb Americas Inc.$1K
  • Coopervision Inc.$755
  • Johnson & Johnson Vision Care, Inc.$474
  • AbbVie$365
  • Harrow Eye, LLC$335
  • plus $715 from 10 others

What the payments were for

  • Travel & lodging$3798%
  • Food & beverage$4,62692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,005 in reported general payments places this provider in the 90th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$46,004
Medicare patients
282
Services billed
481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost107$43,787
RestasisCyclosporine42$37,759
XiidraLifitegrast32$28,288
Cyclosporine24$10,108
Latanoprost249$2,062
Prednisolone Acetate60$1,768
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$1,759
Brimonidine Tartrate50$1,550
Azelastine Hcl29$667
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha33$411
Timolol Maleate53$405
Dorzolamide Hcl13$301
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat31$235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$365$81,545149 claims
Bausch & Lomb Americas Inc.Xiidra$1,049$28,28832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,315 optometrist providers in Texas.

Other optometrist in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →